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Abstract
PRDM1 /BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in 
activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known 
about its genetic aberrations and relevant clinical implications. We assessed a large cohort of 
patients with de novo DLBCL for PRDM1/BLIMP-1 deletion, mutation, and protein expression. 
BLIMP-1 expression was frequently associated with the ABC phenotype and plasmablastic 
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morphologic subtype of DLBCL, yet 63% of the ABC-DLBCL patients were negative for 
BLIMP-1 protein expression. In these patients, loss of BLIMP-1 was associated with Myc 
overexpression and decreased expression of p53 pathway tumor-suppressor molecules. Also, we 
found that homozygous PRDM1 deletions and PRDM1 mutations within exons 1 and 2 which 
encode for domains crucial for transcriptional repression had a poor prognostic impact in patients 
with ABC-DLBCL but not those with germinal center B-cell-like DLBCL. Gene expression 
profiling revealed that loss of PRDM1/BLIMP-1 expression correlated with a decreased plasma-
cell differentiation signature and upregulation of genes involved in B-cell receptor signaling and 
tumor-cell proliferation. In conclusion, these results provide clinical and biological insight into the 
tumor-suppressive role of PRDM1/BLIMP-1 in ABC-DLBCL patients and suggest that loss of 
PRDM1/BLIMP-1 function contributes to the overall poor prognosis of ABC-DLBCL patients.
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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoid malignancy, 
accounting for 30–40% of all non-Hodgkin lymphoma.1 Anthracycline-based combination 
chemotherapy, first introduced in the 1970s, is the backbone of therapy for patients with 
DLBCL, and currently the standard therapy regimen includes the anti-CD20 antibody 
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).2–4 
Despite encouraging complete remission and overall survival (OS) rates using this regimen, 
up to one third of DLBCL patients suffer from relapse or refractory primary disease.5
The heterogeneous clinical outcome of DLBCL results in part from variable genetic profiles 
of this tumor. Gene expression profiling (GEP) has identified two distinct types of DLBCL: 
germinal center B-cell–like and activated B-cell–like (GCB and ABC). Patients with ABC-
DLBCL have markedly poorer survival than do patients with GCB-DLBCL.6, 7 However, the 
molecular mechanism responsible for this difference is not completely understood.
ABC-DLBCL is characterized by constitutive nuclear factor (NF)-κB activation and genetic 
alterations that interfere with terminal B-cell differentiation.8 PRDM1, located on 
chromosome 6q21, encodes for BLIMP-1, a zinc-finger-containing DNA-binding 
transcriptional repressor. BLIMP-1 expression is required for the development of 
immunoglobulin-secreting cells and maintenance of long-lived plasma cells.9 Conditional 
PRDM1-knockout mice do not have production of plasma cells or serum immunoglobulins.
10
 PRDM1 is frequently inactivated in ABC-DLBCL cases as a result of genetic deletions or 
mutations or transcriptional repression of it.11, 12 Studies have demonstrated that an 
inactivation mutation of PRDM1 is recurrent in approximately 25% of ABC-DLBCL cases.
11–14
 Moreover, conditional deletion of PRDM1 in murine B cells facilitates the 
development of lymphoproliferative disease resembling human ABC-DLBCL.8, 11
Limited research has been done on the clinical implications of PRDM1/BLIMP-1 
abnormality in DLBCL patients. In the present study, we investigated PRDM1 deletion and 
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mutation and BLIMP-1 protein expression in a large cohort of de novo DLBCL patients 
treated with R-CHOP. Our results demonstrated that disruption of PRDM1/BLIMP-1 is 
associated with poor prognosis for ABC-DLBCL. We further characterized the potential 
molecular mechanisms underlying the tumor-suppressive function of PRDM1/BLIMP-1 
using GEP.
MATERIALS AND METHODS
Patients
We studied 520 biopsy specimens obtained from R-CHOP-treated patients with de novo 
DLBCL. The diagnostic criteria for DLBCL, patient-selection process, therapy, and 
treatment responses were described previously.15 The study was approved by the 
institutional review boards of the participating institutions.
Immunohistochemistry
Tissue microarrays prepared using formalin-fixed, paraffin-embedded (FFPE) tissue blocks 
of the diagnostic biopsy specimens obtained from the studied patients were stained with an 
anti-BLIMP-1 antibody (EPR16655; Epitomics, Burlingame, CA, USA). BLIMP-1 
expression levels were determined by estimating the percentage of BLIMP-1+ tumor cells in 
the tissue blocks. Evaluation of other biomarkers was performed using 
immunohistochemistry with corresponding antibodies. Details of the immunohistochemical 
procedures and scoring processes were described previously.15–19
Fluorescence in situ hybridization, and PRDM1 and TP53 sequencing
Fluorescence in situ hybridization (FISH) probes spanning the PRDM1 gene and 
chromosome 6 centromere were generated as described previously.13 Dual-color FISH was 
performed using standard procedures. Briefly, 4-μ m-thick tissue sections were backed 
overnight at 56°C, deparaffinized in CitriSolv, treated with 0.2 N hydrochloric acid for 20 
min at room temperature, pretreated with 1 N sodium thiocyanate at 80°C for 30 min, 
protease-digested at 37°C for 50 min, refixed in 10% buffered formalin for 10 min, and 
derehydrated in a 70%, 85%, and 100% ethanol series before hybridization. The tissue 
sections were co-denatured with the addition of a probe for 8 min at 74°C and incubated for 
24 h at 37°C in a hybridization oven (ThermoBrite). Posthybridization washes were 
performed in 0.4× SSC/0.3% NP-40 for 2 min and 2× SSC/0.1% NP-40 for 1 min at 72°C. 
Slides were then mounted with 4,6-diamidino-2-phenylindole (0.5 g/ml) containing an 
antifade solution. For one slide containing 25 cases, 200 nuclei of cells were evaluated 
independently by two observers (A.T. and V.M.). The overall concordance of their 
evaluations was nearly perfect (κ = 0.95), so all other slides (200 nuclei/case) were scored 
by A.T. only. The ratio of PRDM1 signals (green) to CEP6 signals (red) was calculated. If 
this ratio was lower than 0.72, heterozygous PRDM1 deletion was considered to be present. 
Ratios lower than 0.38 were considered to be suggestive of homozygous PRDM1 deletions. 
These ratios were calculated as ratios below the mean plus three standard deviations of green 
to orange signal ratios in reference cases (tonsils; n = 6) and subtraction of tumor-infiltrating 
T cells, which accounted for approximately 30% of undeleted alleles. MYC, BCL2, and 
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BCL6 gene arrangements and copy-number aberrations were detected using FISH, as well.
16, 20
Sequencing of PRDM1 coding regions was performed by Polymorphic DNA Technologies 
(Alameda, CA, USA) using Sanger sequencing. Sequencing results were compared to the 
NCBI NM_001198 reference sequence, followed by exclusion of all the single nucleotide 
polymorphisms (SNPs) documented by NCBI dbSNP database (build 147). The remaining 
variates detected by sequencing were considered as PRDM1 somatic mutations. TP53 was 
sequenced using a p53 AmpliChip (Roche Molecular Diagnostics, Pleasanton, CA, USA) as 
described previously.21
GEP and GCB/ABC classification
GEP was performed using a GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, 
Santa Clara, CA, USA) with total RNAs as described previously.15, 21 The CEL files were 
deposited in the National Center for Biotechnology Information Gene Expression Omnibus 
repository (GSE #31312). GEP classified 407 cases as GCB/ABC subtypes, and the cell-of-
origin of another 111 cases was determined and compared by immunohistochemical 
algorithms (Hans, Visco-Young and Choi).15 Cell-of-origin classification based on B-cell-
associated gene signatures has been described previously.22
MicroRNA profiling
An HTG EdgeSeq Whole Transcriptome Assay (HTG Molecular Diagnostics, Tucson, AZ, 
USA) coupled with a HiSeq system (Illumina, San Diego, CA, USA) was used for 
measuring the expression of microRNAs (miRNAs) in FFPE tissues. Selection of regulatory 
miRNAs for BLIMP-1 expression was based on TargetScan and published data.23–27
Statistical analysis
Clinical and molecular features of patient tumors were compared using the Fisher exact or 
chi-square test. OS and progression-free survival (PFS) in the study population were 
analyzed using the Kaplan-Meier method, and differences between DLBCL subgroups were 
compared using the log-rank test with the Prism 6 software program (GraphPad Software, 
San Diego, CA, USA). Multivariate analysis was performed using the Cox proportional 
hazards regression model with the SPSS software program (version 19.0; IBM Corporation, 
Armonk, NY, USA). P values of up to 0.05 were considered statistically significant.
RESULTS
Patients
The clinical characteristics of the study patients with DLBCL (n = 520) are summarized in 
Table 1. Their median age was 65 years (range, 16–82 years), the median follow-up duration 
was 46.7 months (range, 20.0–186.7 months), and the male : female ratio was 1.2:1. Two 
hundred sixty-eight patients (52%) had GCB-DLBCL, and 250 patients (48%) had ABC-
DLBCL.
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Homozygous PRDM1 deletion predicts poor prognosis for ABC-DLBCL
We detected homozygous deletion of PRDM1 in 19 (7%) of 292 patients with available 
FISH results (Figure 1a and Supplementary Table 1). Patients with homozygous PRDM1 
deletions had lower BLIMP-1 protein expression than did those without these deletions (P = 
0.055, Figure 1a). Homozygous PRDM1 deletion was not associated with the ABC 
phenotype (P = 0.34) or any other clinical parameters. OS was significantly shorter in 
patients with homozygous PRDM1 deletions than in those with normal or heterozygous 
deletions of PRDM1 or monosomy 6 (P = 0.037) (Figure 1b). This difference was 
remarkable in patients with ABC-DLBCL (P = 0.004) but not in those with GCB-DLBCL (P 
= 0.98) (Figure 1b). Homozygous PRDM1 deletion was also associated with significantly 
poorer PFS in the entire DLBCL cohort (P = 0.0048) and in ABC-DLBCL (P = 0.036) 
(Figure 1c). Multivariate analysis adjusting clinical features confirmed homozygous PRDM1 
deletion as an independent prognostic factor for both OS (P = 0.032) and PFS (P = 0.037). In 
the ABC-DLBCL patients, homozygous PRDM1 deletion was an independent prognostic 
factor for OS (P = 0.032) but not for PFS (P = 0.13) (Table 2).
PRDM1 mutation predicts poor prognosis for ABC-DLBCL
We studied PRDM1 mutations in 368 patients with available genomic DNA. Using a quality 
score cutoff of 16 (97% confidence), we identified 94 patients (25.5%) had PRDM1 
mutations within the coding DNA sequence region of PRDM1 (Supplementary Table 2). Of 
these, seven patients had truncating (nonsense) mutations and two had a frameshift mutation. 
Seven of these nine patients had ABC-DLBCL, including four patients with short OS and 
PFS (Supplementary Table 3). PRDM1 mutation was not associated with the ABC 
phenotype (P = 0.91) and did not impact survival in the overall cohort or in GCB-DLBCL 
patients in particular (Supplementary Figure 1). However, PRDM1 mutation did correlate 
with poorer prognosis for ABC-DLBCL (Figure 2a). Moreover, ABC-DLBCL patients 
harboring PRDM1 mutations within exon 1 or 2 had markedly shorter survival durations 
than did patients with mutations in exons 3–7 or wild-type for PRDM1 (Figures 2b–c). In 
comparison, the prognostic impact of exons 1 and 2 PRDM1 mutations on GCB-DLBCL 
was minimal (Supplementary Figure 2). Consistently, we found that patients with exons 1 
and 2 PRDM1 mutations were more likely to have overexpression of both Myc and Bcl-2 
than were patients with exons 3–7 mutations in the overall cohort (P = 0.03) and those with 
wild-type PRDM1 in ABC-DLBCL (P = 0.05) but not in those with GCB-DLBCL (P = 
0.44). Multivariate analysis of clinical parameters, Myc/Bcl-2 expression scores, and 
PRDM1 mutations indicated that Myc/Bcl-2 co-expression (hazard ratio: 2.9, P < 0.001), but 
not PRDM1 mutations (hazard ratio: 1.54, P = 0.12), was an independent prognostic factor.
We also studied the correlations between various types of PRDM1 mutations and BLIMP-1 
protein expression as well as PRDM1 deletion. Patients with nonsense mutations or exon 1/2 
mutations had lower BLIMP-1 expression than patients without these aberrations, but the P 
values for the differences were not significant (Supplementary Figure 3). No significant 
associations were observed between PRDM1 mutations and PRDM1 allelic deletions.
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Loss of BLIMP-1 protein expression correlates with Myc overexpression and decreased 
p53 pathway molecule expression in ABC-DLBCLs
Representative immunohistochemical staining of FFPE tissue sections for BLIMP-1 protein 
expression is shown in Figure 3a. Using a cutoff of 10%, we found that 132 (25%) of the 
520 patients were positive for BLIMP-1. BLIMP-1 protein expression was more common in 
patients with the ABC phenotype (37% vs. 15% in GCB-DLBCL, P < 0.0001) and 
plasmablast subtype22 of DLBCL than others (P < 0.0001; Table 1). The histogram of 
BLIMP-1 expression in the study cohort, and distribution of PRDM1 deletions and 
mutations and BLIMP-1 protein expression in 180 patients with all data available is shown 
in Figure 3b. Ninety-six of these patients were in the ABC subgroup, 59 of whom (61%) had 
BLIMP-1− DLBCL. Thirty-seven (63%) of the BLIMP-1− ABC-DLBCL cases had no 
detectable PRDM1 deletions or mutations. MiRNA profiling identified that miR-30d-3p, 
miR-30d-5p and miR-30b-5p were significantly upregulated in BLIMP-1− patients without 
apparent PRDM1 genetic aberrations, suggesting epigenetic regulations may also play a role 
in loss of PRDM1/BLIMP-1 expression.
In the ABC subgroup, BLIMP-1 negativity was associated with reduced protein expression 
for the NF-κB pathway component p65 (P = 0.028), p53 (P = 0.024; only in subjects wild-
type for TP53), p53 downstream targets MDM2 (P = 0.002) and p21 (P = 0.074). BLIMP-1 
negativity also was more common in patients without expression of CD30 (P = 0.0082) or 
phosphorylated AKT (P = 0.0095) (Table 3). Of note, Myc expression was increased in 
BLIMP-1− cases, with a trend of significance (P = 0.085), and this negative correlation 
between BLIMP-1 and Myc overexpression in ABC-DLBCL was statistically significant 
when using a higher cutoff (≥20%) for BLIMP-1+ (P = 0.0062).
In the GCB subgroup, BLIMP-1 negativity was associated with MYC translocation (P = 
0.049), mutated p53 overexpression, and decreased p21 expression (P = 0.0028) (Table 3). 
We found several other alterations associated with BLIMP-1 negativity in the overall 
DBLCL cohort, including BCL2 translocation (P = 0.004), TP53 mutation (P = 0.005), 
decreased expression of p63 (P = 0.023), nuclear p50 (P = 0.023) and IRF4/MUM1 (P < 
0.0001), increased expression of GCET1 (P = 0.039) and CD10 (P = 0.019), and a lack of 
BCL6 translocation. Bcl-6 expression tended to be upregulated in BLIMP-1− DLBCLs (P = 
0.092), especially in patients with mutated TP53 (P = 0.075).
We did not observe correlations between BLIMP-1 expression and survival in the study 
cohort (Supplementary Figure 4). However, BLIMP-1 negativity had an unfavorable impact 
on OS and PFS in DLBCL patients with TP53 mutations, although the impact was not 
significant (OS, P = 0.12; PFS, P = 0.074) (Figure 3c).
Homozygous PRDM1 deletion contributes to gene expression signatures of transcriptional 
activation
We identified 25 differentially expressed genes (DEGs) between homozygous PRDM1 
deletion-positive and -negative DLBCL cases (Figure 4a). Expression of all of the DEGs 
was upregulated. Subjects with homozygous PRDM1 deletions had robust transcriptional 
activity with upregulation of transcription factors STAT3, HLF, TCF19, TSHZ1, and 
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HMGA2. Accordingly, analysis of the ABC subgroup also identified increased 
transcriptional signatures (Table 4). In contrast, we found no DEGs for homozygous 
PRDM1 deletion in the GCB subgroup.
BLIMP-1 expression signatures in the overall cohort resemble those in ABC-DLBCL
We compared GEP of BLIMP-1− and BLIMP-1+ DLBCL cases in the overall DLBCL 
cohort, in wild-type and mutated PRDM1 subsets (Figure 4a). DEGs were identified in the 
overall DLBCL and the subset with wild-type PRDM1 (147 and 32 DEGs, respectively, with 
a false discovery rate [FDR] threshold of 0.01), but not in the subset with mutated PRDM1, 
suggesting loss of wild-type BLIMP-1 function (Table 4). Loss of BLIMP-1 expression in 
DLBCL was associated with downregulation of PRDM1, X-box binding protein 1 (XBP1), 
which encodes for a critical regulator of plasma differentiation,28 and its downstream target 
genes involved in endoplasmic reticulum, protein synthesis and transportation.29, 30 
Moreover, expression of genes related to immunoglobulin production (ELL2, MGC29506/
MZB1, and ARID3A), cell differentiation (BATF, and IRF4 which transactivates PRDM1 
and represses BCL6 expression31), and B/T cell receptor signaling inhibition (LAX1) was 
also downregulated in BLIMP-1− DLBCLs. In contrast, expression of CD22, MS4A1 which 
encodes for CD20, BCL11A (upregulated during hematopoietic cell differentiation; a B-cell 
proto-oncogene and co-factor with Bcl-6), and BLK which is involved in B cell receptor 
(BCR) signaling was markedly upregulated (1.42-fold, 1.54-fold, 1.67-fold, and 1.2-fold, 
respectively).
DEGs were also identified in the ABC and GCB subgroups (38 DEGs in ABC with a FDR 
threshold of 0.05, Table 4; 22 DEGs in GCB with a FDR threshold of 0.15, Supplementary 
Table 4). When analyzed in the wild-type PRDM1 and mutated PRDM1 subsets separately, 
DEGs were only identified in ABC-DLBCL (but not GCB-DLBCL) with wild-type PRDM1 
(30 DEGs with a FDR threshold of 0.30, Figure 4a and Table 4). The spectrum of DEGs in 
the ABC subgroup was similar to that in the overall cohort, including downregulation of 
PRDM1, XBP1, GHITM, DUSP4, TMEM59, APOBEC3B, FKBP11, DNAJC3, DNAJB9, 
MANF, SEC24A, VDR, TXNDC5, ITGAL, and C12orf55, as well as upregulation of 
BCL11A, CD22, and CLLU1 in BLIMP-1− ABC-DLBCL cases. IGJ was downregulated in 
in BLIMP-1− ABC-DLBCL whereas CD37 antigen was upregulated. In comparison, the 
DEGs identified in the overall GCB-DLBCL (regardless PRDM1 mutation status) also 
included PRDM1, BCL11A, and DUSP4, but were more likely to be involved in immune 
responses (CTLA4, GBP5, C1orf38, HLA-F, and SERPINB1) and metabolism (ACSL1, 
LPCAT2, GTPBP8, CTSA, and METRNL) (Supplementary Figure 5a ).
Considering the potential prognostic impact of BLIMP-1 expression in DLBCL patients 
with mutated TP53, we additionally compared the BLIMP-1 expression signatures in 
patients with mutated TP53 and those wild-type for TP53. Forty-three and 33 DEGs were 
identified respectively in these two subsets with a FDR threshold of 0.20 (Supplementary 
Figures 5b–c and Supplementary Table 4). Comparing these two BLIMP-1 GEP signatures, 
we found PRDM1, SSR1, and HSP90B1 were common signatures. Unique BLIMP-1 
expression signatures in cases wild-type for TP53 included MS4A1/CD20, LAX1, IGJ, 
PRF1, DNAJB9, MOV10, LANCL2, CD2BP2, and IRF1. In the TP53-mutated subgroup, 
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STAT3 which inhibits BCL6 was downregulated in BLIMP-1− cases.32 Other unique 
signatures in DLBCL with mutated TP53 included CFLAR, RBPJ, CMAH, DNAJC13, 
DLEU2, VAMP5, and many others.
PRDM1 mutations within exon 1/2 but not mutations in exons 3–7 showed gene expression 
signatures
We further compared GEP between mutated PRDM1 and wild-type PRDM1 DLBCLs 
regardless of BLIMP-1 expression. In the overall DLBCL and GCB subset, 103 and 193 
DEGs were identified with FDR thresholds of 0.10 and 0.05 respectively. No DEGs were 
identified in the ABC subset, however, probably due to heterogeneity. Similarly, GEP 
comparisons between cases with mutated PRDM1 exon 1/2 and those with wild-type 
PRDM1 only identified DEGs in the overall DLBCL (Supplementary Figure 5d and 
Supplementary Table 5) and GCB (156 DEGs with a FDR threshold of 0.01) but not ABC 
subset. Interestingly, tumor suppressors PTEN and IKZF1 (a transcriptional regulator of 
lymphocyte differentiation) were significantly downregulated in cases with mutated PRDM1 
exon 1/2. In contrast, no significant genes were found differentially expressed between cases 
with mutated PRDM1 exons 3–7 and those with wild-type PRDM1.
DISCUSSION
In this study, we analyzed the clinical and experimental data on 520 de novo DLBCL cases 
to determine the tumor-suppressive function of PRDM1/BLIMP-1. Previous studies 
demonstrated that loss of PRDM1/BLIMP1 function is critical for the pathogenesis of ABC-
DLBCL.8, 11 Herein we provide evidence that loss of PRDM1/BLIMP1 function is a factor 
for poor prognosis for ABC-DLBCL. We found homozygous PRDM1 deletions and PRDM1 
mutations within PRDM1 exons 1 and 2 were poor prognostic factors in patients with ABC-
DLBCL. Loss of BLIMP-1 protein expression was common in ABC-DLBCL and associated 
with a decreased plasma-cell differentiation signature and upregulation of B-cell antigens.
In univariate and multivariate analyses, we found that the prognosis for DLBCL with 
homozygous PRDM1 deletion was worse than that for DLBCL without this deletion. 
However, this homozygous deletion only had prognostic significance in the ABC subgroup, 
as its impact on prognosis for GCB-DLBCLs was minimal. Although the number of patients 
harboring homozygous PRDM1 deletions was small, our GEP still supported reduced 
transcriptional repression in patients with these deletions as suggested by upregulation of 
transcription factors, including ZNF385C, HLF, and HMGA2. Notably, we only observed 
these gene expression signatures in the ABC group.
Similarly, PRDM1 mutations only influenced survival of DLBCL in the ABC subgroup. Our 
data further support this by demonstrating that PRDM1 mutations within exons 1 and 2 still 
significantly affect survival of ABC- but not GCB-DLBCLs. Therefore, we suggest that 
intact BLIMP-1 function is critical for the repression of ABC-DLBCLs. Exons 1 and 2 
encode for the first 97 amino acids of BLIMP-1, including the N-terminal acidic domain. An 
intact N-terminal acidic domain is critical for the normal transcriptional repression function 
of BLIMP-1.33 Researchers showed that BLIMP-1 lacking this domain do not repress the 
MYC promoter.34 Interestingly, all but two of the PRDM1 mutations identified in our cohort 
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were missense mutations. Mandelbaum et al proved that a subset of missense mutations of 
PRDM1 can directly impair BLIMP-1’s protein stability as well as its transcriptional 
repression function, including 2 missense mutations at P48 (corresponding to 84P in this 
article due to different transcripts), the most frequently mutated site within exons 1 and 2 in 
our ABC-DLBCLs.11 Although the decreased BLIMP-1 protein expression in patients with 
PRDM1 mutations within exons 1 and 2 was not significant, we found that mutations in 
exons 1 and 2 were closely correlated with Myc and Bcl-2 co-expression, a previously 
identified marker for poor DLBCL prognosis that was overrepresented in the ABC 
subgroup.18 GEP analysis results reinforced the notion that BLIMP-1 mutations especially 
those in exons 1–2 had lost functions of wild-type BLIMP-1.
At the protein level, although BLIMP-1 expression was frequently associated with the ABC 
phenotype of DLBCL, 63% of the ABC-DLBCL patients lacked BLIMP-1 protein 
expression. Over half of these BLIMP-1− ABC-DLBCL patients had no apparent genetic 
changes in PRDM1. In vitro studies have demonstrated that BLIMP-1 can be inactivated by 
constitutively active Bcl-6.9, 11 We found a negative correlation between Bcl-6 and 
BLIMP-1 expression with borderline significance. Also, expression of BCL11A, a co-factor 
with Bcl-6, was upregulated in our GEP analysis of both ABC and GCB subtypes of 
BLIMP-1− DLBCLs.35 Additionally, PRDM1 can be epigenetically regulated by diverse 
miRNAs including miR-23, miR-9, and let-7a. 23–27 Using miRNA profiling, we found 
upregulation of miR-30d and miR-30b-5p in BLIMP-1− cases without genetic aberrations 
compared to BLIMP1+ cases. Further functional evidence are needed to elucidate the 
regulation between these miRNAs and BLIMP-1 expression.
ABC-DLBCL patients without expression of BLIMP-1 had decreased expression of the 
tumor suppressor protein p53 and its downstream targets MDM2 and p21 as well as 
increased expression of Myc which promotes cell proliferation.36 Therefore, in BLIMP-1− 
DLBCL cases, decreased p53 signaling and Myc overexpression may synergistically 
promote tumor progression. In addition, loss of BLIMP-1 expression was associated with 
dysregulation of NF-κB pathway molecules. Induction of PRDM1 mRNA expression in B-
cell lymphoma cell lines can be blocked by NF-κB inhibitors.37 Recently, Heise et al. 
proved that NF-κB subunit p65 (RELA) is required for the induction of BLIMP-1 
expression, which is consistent with the positive association of p65 expression and 
BLIMP-1+ in our ABC DLBCL cohort.38
Surprisingly, BLIMP-1 protein expression was not a survival predictor in the present study. 
Gyory et al. found that the alternative splicing protein BLIMP-1β, which lacks the first three 
exons in the normal BLIMP-1 protein, does not have transcriptional repression activity.33 
Consistently, detection of BLIMP-1β mRNA expression in tumor cells has been associated 
with poor prognosis for ABC-DLBCL.39 Using our immunohistochemical assay, we could 
not discriminate between the normal BLIMP-1 protein and BLIMP-1β. The presence of 
BLIMP-1β in our cohort may reduce the prognostic impact of normal BLIMP-1 by 
diminishing its ability to repress the activity of downstream targets such as Myc and Bcl-6.
However, lack of BLIMP-1 expression seemed to be an unfavorable prognostic factor for 
DLBCL in patients with aberrant p53 statuses. Kusam et al. reported that Bcl-6 can 
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immortalize primary B cells and greatly increase B-cell function only in the absence of 
normal p53 function.40 BLIMP-1 is a known transcriptional repressor of BCL6.41 We found 
that BLIMP-1 positivity was closely associated with absence of Bcl-6 protein expression in 
our group of DLBCL patients with mutated TP53. Therefore, BLIMP-1 may inhibit the 
proliferation of tumor cells harboring mutated TP53 by repressing Bcl-6 activity. 
Consistently, GEP analysis in DLBCL patients with mutated TP53 found that expression of 
IRF4 and STAT3, activators of BLIMP-1 as well as inhibitors of BCL6, 31, 32 was 
downregulated in BLIMP-1− subgroup.
The BLIMP-1 negativity signature in the overall cohort of DLBCL patients was similar to 
that in the ABC subgroup: both were characterized by downregulation of plasmacytic 
differentiation and upregulation of B cell antigens. BLIMP-1’s role in promoting 
plasmacytic differentiation27 of DLBCL was indicated by downregulation of XBP1 along 
with several of its downstream targets involved in protein synthesis in endoplasmic 
reticulum and transportation in BLIMP-1− cases.42 XBP1 is a transcriptional activator that 
acts downstream of BLIMP-1. BLIMP-1 and XBP1 are jointly required for the 
establishment of terminally differentiated plasma cells.28 Moreover, we found that 
expression of genes involved in immunoglobulin production (ELL2, MZB1, and ARID3A) 
and cell differentiation (BATF) was downregulated in the BLIMP-1− group. On the other 
hand, loss of BLIMP-1 expression in DLBCL correlated with upregulation of CD22 and 
BLK and downregulation of LAX1 that have important roles in regulating BCR signaling. 
Importantly, expression of MS4A1 (encoding CD20) was also upregulated in BLIMP-1− 
cases, possibly indicating an increased therapeutic effect of rituximab in patients with 
BLIMP-1− DLBCL as suggested previously.43, 44 In line with the role of BLIMP-1 in 
plasmacytic differentiation suggested by GEP analysis, the cell-of-origin analysis based on 
B-cell-associated gene signatures22 also showed positive correlation between BLIMP-1 
expression and the plasmablastic subtype of DLBCL (Table 1).
The anti-proliferative effect of BLIMP-1 on DLBCL was also suggested by the GEP results 
as cell-cycle suppressors (e.g., CDKN1B, GADD45A, GHITM, DUSP4) were upregulated 
in BLIMP-1+ DLBCLs. Also, in vitro experiments have demonstrated that B-cell 
proliferation in DLBCL cell lines was promoted upon acute ablation of BLIMP-1 and that 
BLIMP-1 inactivation led to B-cell lymphomagenesis and shortening of life spans in mouse 
models of DLBCL.8, 11 Reintroduction of BLIMP-1 into a DLBCL cell line likely represses 
the cells’ proliferation by turning off MYC and other genes involved in cell-cycle 
progression and DNA repair.45 A brief network of BLIMP-1’s functions and regulation 
generated from our results is presented in Figure 4b.
Collectively, the results of the present study demonstrated that loss of PRDM1/BLIMP-1 
function contributed to the overall poor prognosis for ABC-DLBCL in three ways. First, 
genetic PRDM1 aberrations (including homozygous deletions and mutations) affected the 
prognosis for ABC- but not GCB-DLBCLs. Second, a lack of BLIMP-1 expression 
correlated with an impaired p53 signaling pathway and Myc overexpression in ABC-
DLBCLs. Third, the GEP results for the overall DLBCL patient cohort resembled those for 
the ABC subgroup, both indicating downregulation of plasmacytic differentiation of 
DLBCLs and upregulation of B antigen and BCR signaling in BLIMP-1− tumors. These data 
Xia et al. Page 10
Leukemia. Author manuscript; available in PMC 2018 March 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
may suggest that inactivated BLIMP-1 facilitates DLBCL progression through Myc and 
BCR signaling which are essential for survival of ABC-DLBCL.18, 46 Therapeutic 
approaches that restore the normal function of BLIMP-1 may help drive terminal 
differentiation of tumor cells and overcome the chemoresistance of ABC-DLBCL.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Homozygous PRDM1 deletion in DLBCL cases. (a) Representative examples of FISH 
results with heterozygous PRDM1 deletion (of note are a mixture of cells with two green 
signals, corresponding to centromere 6, but lacking red signals, corresponding to PRDM1, 
and cells with two green signals and one red signal), homozygous PRDM1 deletion (of note 
are two green signals but a lack of red signals in the majority of the cells; one cell in the 
center of the microphotograph has both red and green signals and serves as an internal 
positive control), and monosomy 6 (all cells have only one green and one red signal). 
DLBCL patients with homozygous PRDM1 deletions had lower levels of BLIMP-1 protein 
expression than did the rest of the studied patients. (b–c) The impact of homozygous 
PRDM1 deletion on OS and PFS in all patients with DLBCL, patients with ABC-DLBCL, 
and patients with GCB-DLBCL. Patients with this deletion had shorter OS and PFS 
durations than did patients with normal FISH signals, heterozygous PRDM1 deletions, or 
monosomy 6. This trend was greater in patients with ABC-DLBCL than in GCB-DLBCL.
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Figure 2. 
Correlation of PRDM1 mutations with poor prognosis for DLBCL. (a) In ABC-DLBCL, 
patients with PRDM1 mutations had shorter OS and PFS durations than did patients with 
wild-type PRDM1. (b) PRDM1 mutations within exons 1 and 2 had even greater poor 
impact on OS and PFS compared to did the overall mutation cohort. (c) The detailed 
distribution of PRDM1 mutations within exons 1 and 2.
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Figure 3. 
BLIMP-1 protein expression in DLBCL. (a) Representative immunohistochemical stains of 
DLBCL sections for BLIMP-1 protein expression. (b) The histograms of BLIMP-1 protein 
expression in all DLBCL patients, and the distribution of PRDM1 deletions and mutations 
and BLIMP-1 protein expression in 180 patients with all these three data available. 
Expression of miR-30d-3p and miR-30b-5p was elevated in BLIMP-1− DLBCL patients 
without PRDM1 genetic alterations. (c) The impact of BLIMP-1 protein expression on OS 
and PFS in DLBCL patients with mutated TP53.
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Figure 4. 
Gene expression profiles for the overall and ABC-DLBCL patients and the BLIMP-1 
network in DLBCL. (a) Differential expression of genes between patients with and without 
homozygous PRDM1 deletions, and between patients with and without BLIMP-1 protein 
expression. Differential expression of genes were only found between wild-type BLIMP-1+ 
and BLIMP-1− DLBCLs but not between mutated BLIMP-1+ and BLIMP-1− DLBCLs. (b) 
A brief network of BLIMP-1’s functions and regulations summarizing our results. BLIMP-1 
can be activated by p53, IRF4, and NF-κB signaling. BLIMP-1 represses the transcription of 
MYC, B-cell antigen/surface receptors, and germinal center programs, whereas activates 
LAX1 which inhibits B-cell receptor (BCR) signaling, therefore leading to attenuated BCR 
signaling and decreased tumor cell proliferation. BLIMP-1 also transactivates XBP1 and 
ELL2, which results in activation of plasmacytic differentiation and immunoglobulin 
production.
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